A Study About Fazirsiran in People With and Without Liver Problems.

2023-503735-17-00 Protocol TAK-999-1001 Human pharmacology (Phase I) - Other Ended

Start 5 Oct 2023 · End 4 Sep 2025 · Status Ended · 2 EU/EEA countries · 3 sites · Protocol TAK-999-1001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 41
Countries 2
Sites 3

Hepatic impairment.

Key facts

Sponsor
Takeda Development Center Americas Inc.
Participant type
Healthy volunteers, Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
5 Oct 2023 → 4 Sep 2025
Decision date (initial)
2023-09-07
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Hepatic impairment.

VersionLevelCodeTermSystem organ class
22.1 LLT 10052254 Hepatic impairment 10019805

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Takeda Development Center Americas Inc.

Sponsor organisation
Takeda Development Center Americas Inc.
Address
500 Kendall Street
City
Cambridge
Postcode
02142-1108
Country
United States

Scientific contact point

Organisation
Takeda Development Center Americas Inc.
Contact name
Nirav Desai

Public contact point

Organisation
Takeda Development Center Americas Inc.
Contact name
Takeda

Locations

2 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Hungary Ended 22 1
Slovakia Ended 19 2
Rest of world 0

Investigational sites

Hungary

1 site · Ended
CRU Hungary Kft.
Early Phase Unit, Semmelweis Ter 1, 2143, Kistarcsa

Slovakia

2 sites · Ended
Summit Clinical Research s.r.o.
NA, Bardosova 2a, 831 01, Nove Mesto
Summit Clinical Research s.r.o.
NA, Duklianskych Hrdinov 34, 901 01, Malacky

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Hungary 2023-10-05 2025-06-16 2023-10-05 2025-03-15
Slovakia 2023-10-17 2025-09-03 2023-10-17 2025-03-15

Application history

8 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-05-15 Hungary Acceptable
2023-09-01
2023-09-04
2 NON SUBSTANTIAL MODIFICATION NSM-1 2023-11-17 Hungary Acceptable
2023-09-01
2023-11-17
3 SUBSTANTIAL MODIFICATION SM-1 2024-04-12 Hungary Acceptable
2024-05-22
2024-05-22
4 NON SUBSTANTIAL MODIFICATION NSM-2 2024-06-11 Hungary Acceptable
2024-05-22
2024-06-11
5 NON SUBSTANTIAL MODIFICATION NSM-3 2024-06-12 Hungary Acceptable
2024-05-22
2024-06-12
6 SUBSTANTIAL MODIFICATION SM-2 2024-07-08 Hungary Acceptable
2024-08-03
2024-08-03
7 SUBSTANTIAL MODIFICATION SM-3 2024-11-21 Hungary Acceptable
2025-02-03
2025-02-03
8 NON SUBSTANTIAL MODIFICATION NSM-5 2025-05-09 Hungary Acceptable
2025-02-03
2025-05-09